ABSTRACT Background. Determination of the profile of genes that are commonly methylated aberrantly in colorectal cancer (CRC) will have substantial value for diagnostic and therapeutic applications. However, there is limited knowledge of the DNA methylation pattern in CRC. Materials and Methods. We analyzed the methylation profile of 27,578 CpG sites spanning more than 14,000 genes in CRC and in the adjacent normal mucosa with bead-chip array-based technology. Results. We identified 621 CpG sites located in promoter regions and CpG islands that were greatly hypermethylated in CRC compared to normal mucosa. The genes on chromosome 18 showed promoter hypermethylation most frequently. According to gene ontology analysis, the most common biologically relevant class of genes affected by methylation was the class associated with the cadherin signaling pathway. Compared to the genome-wide expression array, mRNA expression was more likely to be downregulated in the genes demonstrating promoter hypermethylation, even though this was not statistically significant. We validated ten CpG sites that were hypermethylated (ADHFE1, BOLL, SLC6A15, ADAMTS5, TFPI2, EYA4, NPY, TWIST1, LAMA1, GAS7) and 2 CpG sites showing hypomethylation (MAEL, SFT2D3) in CRC compared to the normal mucosa in the array studies using pyrosequencing. The methylation status measured by pyrosequencing was consistent with the methylation array data. Conclusions. Methylation profiling based on bead-chip arrays is an effective method for screening aberrantly methylated genes in CRC. In addition, we identified novel methylated genes that are candidate diagnostic or prognostic markers for CRC.
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Colorectal cancer (CRC) is one of the most common cancers in the world. CRC arises as a consequence of the accumulation of genetic alterations and epigenetic alterations that transform colonic epithelial cells into adenocarcinoma cells. 1 The aberrant methylation of CpG islands in the promoter or exon 1 regions of the genes is a recognized epigenetic event that silences the tumor suppressor genes in CRC. 2, 3 These aberrantly methylated genes are promising biomarkers for molecular diagnostics and early detection and are attractive predictive markers for targeted therapies. 4 The CRC can be prevented through a resection of colorectal adenoma and is treated most effectively when detected at an early stage. A regular colonoscopic examination is recommended, but the high cost and invasiveness of the procedure is an obstacle to its application as a screening test for CRC. Furthermore, although fecal occult blood testing is inexpensive and noninvasive, the sensitivity and specificity of this test are low. [5] [6] [7] Therefore, more accurate biomarkers and methods for the early detection of CRC, such as fecal DNA-based tests, are needed. [8] [9] [10] [11] Fecal DNA tests that use genetic mutations are complicated, generally expensive, and inadequately sensitive to adenomas. Recent studies showed that the aberrant DNA methylation of several genes is present in even the earliest steps in the adenoma-carcinoma sequence, such as the aberrant crypt focus. [12] [13] [14] [15] Moreover, many genes were silenced by aberrant methylation and might be associated with colorectal tumorigenesis. [16] [17] [18] [19] [20] [21] Therefore, the genes with aberrant methylation have the potential to be useful biomarkers for the early detection of colorectal tumors. The ability to detect aberrant DNA methylation from the DNA extracted from a range of samples, including blood, stool, and paraffin-embedded formalin-fixed tissue, suggests that these assays are robust with excellent potential to be used clinically. [22] [23] [24] In addition, the DNA methylation patterns can be applied to the molecular classification of neoplasms as well as to the prediction of the therapeutic responsiveness and prognosis of CRC. [25] [26] [27] [28] [29] Finally, epigenetic therapy, such as 5-azacitidine, has been shown to be effective in treating hematologic malignancies and might be useful for treating CRC. 30 As our understanding of the role of epigenetic alterations in the carcinogenesis of CRC increases, epigenetic therapy for CRC might be realized. In addition, identification of the signaling pathways deregulated by aberrant DNA methylation may provide a means of selecting CRCs that will be particularly sensitive to targeted therapies. 31 A comprehensive assessment of the aberrantly methylated genes in CRCs has the potential not only to improve our understanding of the molecular biology of CRC, but also to identify the methylated genes that will influence the clinical care of the patients with CRC. Therefore, this study analyzed the methylation profile of 27,578 CpG sites spanning more than 14,000 genes in CRC tissue and the adjacent normal tissue with bead-chip array-based technology. 32, 33 
MATERIALS AND METHODS

Subjects
Twenty-two pairs of CRC and adjacent normal mucosa were collected from the patients treated at Samsung Medical Center (Seoul, Korea) for methylation profiling (Table 1) . Another 35 and 65 pairs were obtained to validate the candidate genes selected from methylation profiling using pyrosequencing analysis and genome-wide expression array, respectively ( Table 1) . The protocol of this study was approved by the institutional review board. None of the patients had clinically apparent polyposis syndrome or Lynch syndrome. The DNA was extracted from snap-frozen sections from these tumors and normal mucosa using a DNeasy Tissue kit (Qiagen) according to the manufacturer's protocol.
Methylation Profiling in CRC and Normal Mucosa
Human Methylation27 DNA Analysis BeadChip (Illumina) was used to analyze the methylation profile of the CRCs. This bead-chip array can provide methylation information at a single-base resolution for 27,578 CpG sites spanning more than 14,000 genes.
All the samples were bisulfite converted with an EZ DNA methylation kit (Zymo Research) according to the manufacturer's instructions. After whole-genome amplification with 200 ng of input bisulfite-converted DNA, the product was fragmented, purified, and applied to the bead chips using Illumina-supplied reagents and conditions. After extension, the array was stained fluorescently and scanned, and the intensities of the unmethylated and methylated bead types were measured.
Thirty-five targets of the 27,578 targets with a detection P value of [0.05 were excluded, and the remaining 27,543 target CpG sites were used in the final analysis. Each methylation data point is represented by the fluorescent signals from the M (methylated) and U (unmethylated) alleles. The background intensity calculated from a set of negative controls was subtracted from each analytical data point. The ratio of fluorescent signals was then computed from the two alleles b = (max(M, 0))/(|U| ? |M| ? 100). The c value reflects the methylation level of each CpG site. A b value of 0-1.0 indicates the percent methylation from 0 to 100%, respectively, of each CpG site. The difference in the mean b value (Db) means (mean of b-value in CRC -mean of b-value in normal mucosa). Statistical significance of the methylation data was determined by a paired t test based on the null hypothesis that no difference exists between the means of CRC and normal mucosa in the methylation data. The false discovery rate was controlled by adjusting the P value with the BenjaminiHochberg algorithm. Hierarchical clustering was performed by complete linkage with a Euclidian metric. Gene ontology analysis for the genes with hypermethylated promoters in CpG islands was performed by the PANTHER classification system (http://www.pantherdb.org/panther/ontologies.jsp) using the text files containing the Gene ID list and accession number of Illumina probe ID.
Genome-Wide Expression Array in CRC
The total RNA was extracted with the RNeasy Mini Kit (Qiagen) according to the manufacturer's protocol. The RNA samples were labeled according to the chip manufacturer's recommended protocols. Briefly, 0.5 lg of total RNA from each sample was labeled with the Illumina Total Prep RNA Amplification Kit (Ambion) in a process of cDNA synthesis and in vitro transcription. Single-stranded RNA (cRNA) was generated and labeled by incorporating biotin-NTP (Ambion). A total of 1.5 lg of biotin-labeled cRNA was hybridized at 58°C for 16 h to the Illumina's Sentrix Human-6 v2 Expression BeadChip (Illumina). The hybridized biotinylated cRNA was detected with streptavidin-Cy3 and quantitated with Illumina's BeadArray Reader Scanner (Illumina) according to the manufacturer's instructions. The array data were processed and analyzed by Illumina BeadStudio version 3.0 software. Data normalization was performed by quantile normalization, and the fold changes and statistical significance were determined by Avadis Prophetic version 3.3 (Strand Genomics).
Validation of Methylation Status with Pyrosequencing Analysis
The promoter region of the 12 genes (ADHFE1, BOLL, SLC6A15, ADAMTS5, TFPI2, EYA4, NPY, TWIST1, LAMA1, GAS7, SFT2D3, and MAEL) were amplified using the forward primer and biotinylated reverse primer, which were designed by PSQ Assay Design (Biotage AB). The official full names of gene symbols are listed in supplementary Table 1 . The bisulfite-modified DNA was amplified in a 25-ll reaction with the primer set and f-Taq polymerase (Solgent). The samples were heated to 95°C for 2 min and amplified for 50 cycles of the following: 95°C for 30 s, 58-63°C for 30 s, and 72°C for 30 s, followed by a final extension step at 72°C for 5 min. Pyrosequencing reactions were carried out with a sequencing primer on the PSQ HS 96A System (Biotage AB) according to the manufacturer's specifications. Supplementary Table 2 lists the primer sequences.
RESULTS
Methylation Profiling in CRC
The methylation status of the 27,578 CpG sites in 22 pairs of CRC tissue and adjacent normal mucosa were measured to identify the genes that are commonly methylated aberrantly in CRC. We selected 3622 CpG sites with an adjusted P \ 0.001 and a minimum Db of 0.15. The CpG sites in CpG islands were more likely to be hypermethylated compared to the CpG site outside CpG islands (supplementary Table 3 ). Six hundred twenty-one (6.3%) of the 9792 CpG sites located in promoter regions and CpG islands were found to be greatly hypermethylated in CRC compared to the normal mucosa. Table 2 lists the 20 topranking genes with hypermethylated or hypomethylated promoters in CpG islands. Hierarchical clustering with the differentially methylated CpG sites showed clear demarcation between CRC and normal mucosa. Genes with hypermethylated or hypomethylated promoters in CpG islands were generally found on all chromosomes (Fig. 1) . However, there were differences between chromosomes. 
Validation of Methylation Status by Pyrosequencing Analysis
Ten CpG sites showing hypermethylation and two CpG sites showing hypomethylation in CRC compared to the normal mucosa were validated by pyrosequencing to confirm the methylation state of the genes identified to be aberrantly methylated in CRC by the array studies. Among the ten hypermethylated CpG sites, four CpG sites (ADHFE1, BOLL, SLC6A15, and ADAMTS5) were selected because these genes were the most highly methylated in CRC compared to the normal mucosa, and six CpG sites (TFPI2, EYA4, NPY, TWIST1, LAMA1, and GAS7) were selected on the basis of our previous GoldenGate Methylation Solution (Illumina) results (unpublished) or genomewide expression array data. The two hypomethylated CpG sites (MAEL and SFT2D3) were selected because these genes showed the lowest methylation level in tumor tissue compared to the normal mucosa. The methylation status measured by pyrosequencing showed a good correlation with the methylation status measured by Human Methylation27 DNA Analysis BeadChip (Fig. 2) . This result showed that DNA methylation profiling using bead-chip arrays is an accurate method for the genome-wide screening of methylated CpG sites.
Gene Ontology Categories of Hypermethylated or Hypomethylated CpG Sites
Gene ontology analysis of the hypermethylated or hypomethylated CpG sites located in promoter regions and CpG islands in CRC was performed. The aberrantly methylated CpG sites were distributed across various categories of biological processes, molecular functions or pathways. However, the promoters of the genes related to certain categories appeared to be more likely to be hypermethylated (Table 3) . Interestingly, the genes in cadherin signaling pathway were mostly frequently hypermethylated.
Comparison of Promoter Hypermethylation to CAN Genes
MLH1 can be inactivated genetically and epigenetically. A germ-line mutation of MLH1 causes Lynch syndrome, and promoter hypermethylation of MLH1 causes microsatellite unstable sporadic CRC. Therefore, this study examined whether the promoter of CAN genes, described by Sjoblom et al. 34 showed hypermethylation. Thirty-seven out of 69 CAN genes had promoter regions in the CpG islands, and 6 of these 37 genes (CHL1, CSMD3, EYA4, GUCY1A2, KCNQ5, and MMP2) showed marked promoter hypermethylation (Table 4) . These results are consistent with those reported by Schuebel et al. 35 
Comparison of Promoter Hypermethylation to Genome-wide Expression Array Data
Finally, genome-wide expression array analysis was performed comparing six normal colonic mucosa samples versus 65 CRC tissues to determine the relationship between the gene methylation status and mRNA expression of genes. This approach was used to obtain a preliminary
FIG. 1 Chromosomal distribution of hypermethylated or hypomethylated promoters in CpG islands.
Percentage indicates (number of hypermethylated or hypomethylated CpG sites 9 100/number of total CpG sites located in promoter regions and CpG islands on individual chromosome). This shows that genes on chromosome 18 are hypermethylated most frequently assessment of the proportion of genes that were aberrantly methylated ''passenger'' genes versus ''driver'' genes. The mean fold change was the log ratio of the mRNA expression level for the CRC tissue relative to six pooled normal mucosa. There was no statistically significant difference in the mRNA expression level between promoter   FIG. 2 Pyrosequencing analysis. Methylation level of ten hypermethylated genes (ADHFE1, BOLL, SLC6A15, ADAMTS5, TFPI2, EYA4, NPY, TWIST1, LAMA1, and GAS7) and two hypomethylated genes (MAEL and SFT2D3) was confirmed by pyrosequencing analysis hypermethylation group and hypomethylation group (supplementary Table 4 ). However, mRNA expression was more likely to be downregulated in the promoter hypermethylation group, even though it was not statistically significant. The genes with promoter hypermethylation whose expression was downregulated more than twofold are as follows: ADHFEI, SCNN1B, C2orf32, SLIT2, ECH-DC3, SLIT3, EFEMP1, SST, FOXD2, ST3GAL4, FRZB, TCEAL2, HOXA5, UCHL1, NDRG2, ZFHX1B, NPY, ZNF447, and PPP1R3C. The genes with promoter hypomethylation whose expression was upregulated more than twofold are as follows: C19orf33, IL10RA, ECH1, MTM1, and HMGCL.
DISCUSSION
A genome-wide assessment of the methylation state of CpGs in CRC was assessed by Human Methylation27 DNA Analysis BeadChip arrays. This array platform was found to be a promising method for identifying the genes with promoter hypermethylation in CRC. These results are consistent with the published genome-wide assessments of aberrantly methylated genes in CRC. Schuebel et al. 35 reported that epigenetic unmasking techniques using expression arrays identified the genes affected by promoter CpG island DNA hypermethylation. They confirmed the methylation status of several candidate genes in CRC and normal tissue using nested methylation-specific polymerase chain reaction. The results of their validation studies identified the genes that were found in the present study to be methylated in CRCs. For example, BOLL, EFEMP1, and JPH3 were significantly methylated in both studies. Estécio et al. 36 used the methylated CpG island amplification method to identify the methylated genes in the RKO CRC cell line. Sixty-three of the genes that Estécio et al. 36 found to be methylated using the methylated CpG island amplification method were represented on the HumanMethylation27 arrays. Among these 63 genes, 6 genes (GDNF, GFRA1, HAND2, OTP, PRDM14, and WT1) were significantly methylated in our studies. Furthermore, Mori et al. 37 used epigenetic unmasking to identify 54 genes that showed CRC-specific promoter methylation. Among the candidate genes, the promoters of NELL1, AKAP12, MAL, SST, and TAC1 were significantly methylated in our results. Finally, methylated DNA immunoprecipitation was used to identify aberrantly methylated genes in the CRC through its application to the CRC cell line. Among the genes identified as hypermethylated in SW48, we found that two genes, ADAM12 and ZNF677, were hypermethylated in the CRC tissue compared to normal tissue. 38 To our knowledge, this study is the first report of methylation profiling using Human Methylation27 DNA Analysis BeadChip in CRC. A comparison of our results demonstrated modest overlap in the genes found to be commonly methylated in CRCs compared to previously published studies. This may represent differences in the sensitivity of the assays, differences between the cell lines and primary tumors or differences in the epigenome of tumors that occur in Western populations versus Asian populations.
We obtained a list of 621 genes with the hypermethylated promoter in CpG islands. It is postulated that the number of epigenetically altered genes is higher than genetically altered genes in tumor tissue. 35 However, the expression of all the 621 hypermethylated genes was not downregulated in the CRC tissue compared to normal mucosa. The correlation between promoter hypermethylation and the mRNA expression level was modest at best, even though mRNA expression tended to be downregulated in the genes showing promoter hypermethylation. This likely reflects the fact that many epigenetic and genetic alterations in cancers are passenger events that are not important in the pathogenesis of cancer. 39 Moreover, multiple mechanisms regulate gene expression in addition to methylation, and these mechanisms are altered in CRC, which confound our ability to identify a correlation between methylation and gene expression. Although the expression is not downregulated, cancer-specific promoter hypermethylation can be valuable as a biomarker.
The following interesting patterns were identified through an analysis of the methylome of CRCs: (1) genes on chromosome 18 were most frequently methylated; (2) CAN genes can be affected by mutations and aberrant methylation; and (3) genes involved in cadherin function are often subject to aberrant DNA methylation. A previous study showed that the genes on chromosome 18 were most frequently downregulated in rectal cancer. 40 In addition, a loss of chromosome 18 occurs at early stages of colorectal carcinogenesis. 41 This suggests that the aberrant methylation of genes appears to cooperate with the genetic alterations to drive the initiation and progression of CRC. 42 In comparison of our result with the CAN genes of Sjoblom et al. 34 , we could get the methylation level of 37 CAN genes with the promoter in CpG islands and the promoters of 6 genes were hypermethylated. This proportion is meaningful considering that some of the 37 genes can have an oncogenic effect. Ontology analysis of the genes showed that promoter hypermethylation occurred at various biological processes and molecular functions. Among them, the cadherin-signaling pathway attracted attention. The cadherin gene family (E-cadherin, N-cadherin, and P-cadherin) encodes the proteins that mediate calcium-iondependent adhesion. Cadherin-catenin complex is the central part of this pathway. It has been suggested that they are involved in colorectal carcinogenesis.
This study identified new candidates of methylation markers for CRC. Ten genes with promoter hypermethylation were validated by pyrosequencing analysis. To our knowledge, seven genes have not been reported to undergo DNA methylation in CRC. TFPI2 is a Kunitz-type serine proteinase inhibitor that protects the extracellular matrix of cancer cells from degradation and inhibits in vitro colony formation and proliferation. 43 Promoter hypermethylation of TFPI2 was observed in various cancers, including esophageal cancer, gastric cancer, pancreatic cancer, cervical cancer, and malignant melanoma. [44] [45] [46] [47] [48] [49] [50] Methylation of TFPI2 in stool DNA was recently reported to be a potential novel biomarker for the detection of CRC. 43 EYA4 encodes a protein acing as a transcriptional activator through its protein phosphatase activity, which is important for eye development and for the continued function of the mature organ of Corti. 51 Aberrant methylation was observed in esophageal and CRC. 52, 53 BOLL belongs to the DAZ gene family that is required for germ cell development. One report showed that BOLL was hypermethylated in colon cancer cell lines. 35 Other genes were reported to be associated with carcinogenesis. For example, TWIST1 promoter methylation was reported to be far more prevalent in malignant breast tissue than in healthy tissue. 54 NPY can reduce the invasive potential of colon cancer cells in vitro. 55 Further study will be needed to confirm the usefulness of these promoter hypermethylation as biomarkers and clarify the functional role of these genes in colorectal carcinogenesis. In addition, it is important to validate the methylation status and clarify the functional role of the genes with promoter hypermethylation, in which expression was downregulated in CRC.
In conclusion, we have shown that methylation profiling based on bead-chip arrays is an effective method for screening the genes with promoter hypermethylation. In addition, we identified new potential candidates of methylation markers in CRC.
